• Viridian Therapeutics Inc (NASDAQ: VRDN) has announced initial data from the 10mg/kg cohort in its ongoing Phase 1/2 trial of VRDN-001 for thyroid eye disease (TED), a rare autoimmune disease in which the body's immune system attacks the tissues around and behind the eyes.

• Significant and rapid improvement in both signs and symptoms of TED at week six after two infusions of 10mg/kg VRDN-001.

• Proptosis (bulging eyes) response was achieved by 83% of patients with a mean reduction of 2.4mm from baseline.

• A clinical Activity Score of 0 or 1 was achieved by 83% of patients with a mean reduction of 4.3 points from baseline.

• 75% of the patients achieved complete resolution of diplopia (double vision).

• Demonstrated a favorable safety and tolerability profile with no reported SAEs, no hyperglycemia, and no infusion reactions.

• Two cases of mild muscle spasms were reported and did not require intervention. One report of "ringing in the ears" resolved within two weeks without intervention.

• No serious adverse events were reported in the ongoing TED cohort, evaluating two infusions of 20mg/kg of VRDN-001.

• Data from the 3mg/kg cohort is expected in Q4 of 2022.

• The first VRDN-001 Phase 3 trial (THRIVE) in active TED patients is expected to initiate by the end of 2022, with topline data expected in mid-year 2024.

• The second VRDN-001 Phase 3 trial (THRIVE-2) in chronic TED is expected to initiate in 1H of 2023, with topline data by the end of 2024.

• Price Action: VRDN shares are up 31.4% at $19.35 during the premarket session on the last check Monday.

See more from Benzinga

• Plus Therapeutics Shares Surge On Positive Data From Lead Brain Cancer Candidate

• Seagen Suffers Loss In Arbitration Dispute Over ADC Technology

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.